Lifecare ASA will release its third quarter 2024 results on Wednesday 13
November 2024 at 07:00 a.m. CET.
The same day at 11:00 CET, the CEO Joacim Holter will present the results live
at Carnegie AS, Fjordalleen 16, Aker Brygge in Oslo.
After the presentation, Lifecare invites to 1:1 session with the CEO and the
CFO.
To register for physical attendance and 1:1 meeting, please send an email to
ca@carnegie.no (mailto:ca@cartnegie.no). To access the live webcast Join the
Teams-meeting here
(https://teams.microsoft.com/l/meetup-join/19%3ameeting_ZmFmNTAzNTQtM2M2YS00Mjg1LWJlNjEtMGM0YzcxY2U5MWE1%40thread.v2/0?context={"Tid"%3a"904e2f8f-5832-43bf-aea8-7cbfde1c5d4c"%2c"Oid"%3a"382475a7-cf90-4587-b322-8c2dfa57332e"})
About us
Lifecare ASA is a clinical stage medical sensor company developing technology
for sensing and monitoring of various body analytes. Lifecare's main focus is
to bring the next generation of Continuous Glucose Monitoring ("CGM") systems
to market. Lifecare enables osmotic pressure as sensing principle, combined
with the ability to manipulate Nano-granular Tunnelling Resistive sensors
("NTR") on the sensor body for read-out of pressure variations. Lifecare's
sensor technology is referred to as "Sencell" and is suitable for identifying
and monitoring the occurrence of a wide range of analytes and molecules in the
human body and in pets.
Contacts
For further information, please contact:
Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40
Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42